About this episode
Following its latest contract win with Traws Pharma, hVIVO #HVO outlines how its ability to deliver human challenge trials, recruitment and lab services under one roof is resonating with clients. The interview explores the benefits of larger, more sophisticated studies and why influenza remains a key area for rapid, controlled clinical insights.
Get every episode summarized
Each time The Vox Markets Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Vox Markets Podcast
2369: Poolbeg hits significant milestone with POLB 001
The Vox Markets Podcast
2368: hVIVO FY25 Results: Growth, Acquisitions and What Comes Next in 2026
The Vox Markets Podcast
2367: Quantum Data Energy CEO on Q1 Progress
The Vox Markets Podcast
2366: Chancery Royalty gets set for US$7,000 gold
The Vox Markets Podcast